Skip to main content

Table 4 Adverse reactions observed at the clinic and within 10 days of a melarsomine injection

From: Improving access to melarsomine therapy: treating canine heartworm infection in a high-volume, outpatient community clinic setting

Adverse effect

Appointment type

Number of dogs

Total Dogs

Percentage (%)

VT/VA-observed adverse reactions at the clinic

 All adverse reactions

 

483

539

90

 

Injection 1

366

479

76

 

Injection 2

354

518

68

 

Injection 3

288

468

62

 Behavioral

 

465

539

86

 

Injection 1

340

478

71

 

Injection 2

342

518

63

 

Injection 3

243

468

52

 Local injection site

 

177

539

33

 

Injection 1

80

477

17

 

Injection 2

67

515

13

 

Injection 3

92

468

20

 Respiratory

 

3

539

0.6

 

Injection 1

1

477

0.2

 

Injection 2

2

515

0.4

 

Injection 3

1

468

0.2

 Gastrointestinal

 

16

539

3.0

 

Injection 1

3

477

0.6

 

Injection 2

7

515

1.4

 

Injection 3

6

468

1.3

 Immediate hypersensitivity

 

1

539

0.2

 

Injection 1

0

477

0

 

Injection 2

1

515

0.2

 

Injection 3

0

468

0

Owner-observed adverse reactions 10 days following a melarsomine injection

 All adverse reactions

 

314

539

58

 

Injection 1

244

505

48

 

Injections 2/3

186

389

48

 Behavioral

 

166

539

31

 

Injection 1

125

467

27

 

Injections 2/3

81

349

23

 Local injection site

 

215

539

40

 

Injection 1

156

502

31

 

Injections 2/3

130

367

35

 Respiratory

 

104

539

19

 

Injection 1

78

503

16

 

Injections 2/3

55

388

14

 Gastrointestinal

 

136

539

25

 

Injection 1

93

467

20

 

Injections 2/3

73

349

21

  1. Samples sizes vary based on missing data points within each case